Enteric Coated And Controlled Release Tablets And Capsules Market Size Projected to Reach $103.08 million by 2034 | 6.6%

Bacterial vaginosis (BV) is an overgrowth of typical bacteria in the vagina. It is extremely prevalent in the U.S. As per the CDC, over 22 million women between the ages of 14–49 are suffering from bacterial vaginosis in the U.S. Globally, BV is highly prevalent in the developing countries, including Asia-Pacific, Latin America, and the Middle East and Africa, which is further driving the antibiotic and antibacterial drug segment growth. Moreover, gelatin and HPMC are extensively used for coating the antibiotic and antibacterial drug tablets and capsules as it extends the shelf life, prevents contamination, and ensures drug stability.

In the last few years, the prevalence of cardiovascular diseases and inflammatory diseases, such as autoimmune diseases, asthma, coeliac disease, glomerulonephritis, allergy, reperfusion injury, hepatitis, inflammatory bowel disease, and transplant rejection, is increasing at a concerning rate due to hereditary purposes and sedentary lifestyle. Asthma is one of the most common non-communicable diseases, which has subsequently increased the consumption of anti-inflammatory drugs by seven-folds. As per the Global Asthma Network (GAN) and the study conducted by the Global Burden of Disease (GBD), in 2016, over 39.4 million people had asthma across the globe.

Regional Insights

North America leads the tablet part of the enteric-coated and controlled-release tablets and capsules market.

Europe’s enteric-coated and controlled-release tablets and capsules market is largely driven by the increasing consumption of antibiotic and antibacterial drugs, antacids, and other anti-inflammatory medications. As per the ECDC, in Europe, over 42,844 people suffered from the influenza virus during 2018–2019. Thereby, the rising prevalence of infectious diseases in the U.K., Norway, Ireland, Portugal, and Denmark, is subsequently boosting the market growth.

Key Highlights

• The gelatin capsules segment is projected to grow with a significant CAGR of 7.3% on account of the increasing prevalence of severe and life-threatening diseases, rising healthcare expenditure, and rapidly growing consumption of medicines for several treatments
• North America holds the largest market share in the enteric and changed release capsules market

Market Segments

By Type

• Tablets
  • Gelatin Coating
  • Hydroxypropyl Methylcellulose (HPMC) Coating
• Capsules
  • Gelatin
  • Hydroxypropyl Methylcellulose (HPMC)

By Application

• Antibiotic and Antibacterial Drug
• Vitamins and Dietary Supplement
• Proton Pump Inhibitors
• Anti-Inflammatory Drugs
• Cardiovascular Therapy Drug
• Neurological Drug

By Region

• North America
• Europe
• Asia-Pacific
• Central and South America and the Caribbean
• The MiddleEast and Africa